BRAF and neoplasm: For patients with RAS and BRAF mutations, triplet chemotherapy and combinations with bevacizumab represented two rational alternatives on the basis of high response rates and tumor shrinkage [30]; however their efficacy in the conversion setting has yet to be confirmed in specifically designed studies.